
 
 
 
 
 
 
 
 
   
 141204-01, the humanized antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01 or the chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01, comprising: 95 WO 2009/023955 PCT/CA2008/001452 providing a tissue sample from said human tumor; providing at least one of said isolated monoclonal antibody, said humanized antibody, said chimeric antibody or CDMAB thereof that recognizes the same epitope or epitopes as those recognized by the isolated monoclonal antibody produced by a hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01; contacting at least one said provided antibodies or CDMAB thereof with said tissue sample; and determining binding of said at least one provided antibody or CDMAB thereof with said tissue sample; whereby the presence of said cancerous cells in said tissue sample is indicated. Claim 48. A binding assay to determine the presence of cells which express CD9 which is specifically recognized by the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-0 1, the humanized antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01 or the chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-0 1, comprising: providing a cell sample; providing the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, said humanized antibody, said chimeric antibody or CDMAB thereof; contacting said isolated monoclonal antibody or said antigen binding fragment with said cell sample; and determining binding of said isolated monoclonal antibody or CDMAB thereof with said cell sample; whereby the presence of cells which express an antigen of CD9 which is specifically bound by said isolated monoclonal antibody or said CDMBA thereof is determined. Claim 49. A binding assay to determine the presence of primate cells which express CD9 which is specifically recognized by the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, the humanized 96 WO 2009/023955 PCT/CA2008/001452 antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01 or the chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204 01, comprising: providing a primate cell sample; providing the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, said humanized antibody, said chimeric antibody or CDMAB thereof; contacting said isolated monoclonal antibody or said antigen binding fragment with said primate cell sample; and determining binding of said isolated monoclonal antibody or CDMAB thereof with said primate cell sample; whereby the presence of primate cells which express an antigen of CD9 which is specifically bound by said isolated monoclonal antibody or said CDMBA thereof is determined. Claim 50. A binding assay to determine the presence of rabbit cells which express CD9 which is specifically recognized by the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, the humanized antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01 or the chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204 01, comprising: providing a rabbit cell sample; providing the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, said humanized antibody, said chimeric antibody or CDMAB thereof; contacting said isolated monoclonal antibody or said antigen binding fragment with said rabbit cell sample; and determining binding of said isolated monoclonal antibody or CDMAB thereof with said rabbit cell sample; 97 WO 2009/023955 PCT/CA2008/001452 whereby the presence of rabbit cells which express an antigen of CD9 which is specifically bound by said isolated monoclonal antibody or said CDMBA thereof is determined. Epitope Sequence-not yet determined Claim 51. A monoclonal antibody which specifically binds to the same epitope or epitopes as the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01. Claim 52. An isolated monoclonal antibody or CDMAB thereof, which specifically binds to human CD9, in which the isolated monoclonal antibody or CDMAB thereof reacts with the same epitope or epitopes of human CD9 as the isolated monoclonal antibody produced by a hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01; said isolated monoclonal antibody or CDMAB thereof being characterized by an ability to competitively inhibit binding of said isolated monoclonal antibody to its target human CD9 antigen. Claim 53. An isolated monoclonal antibody or CDMAB thereof that recognizes the same epitope or epitopes as those recognized by the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01; said monoclonal antibody or CDMAB thereof being characterized by an ability to competitively inhibit binding of said isolated monoclonal antibody to its target epitope or epitopes. CDR Sequence Claim 54. A monoclonal antibody that specifically binds the same epitope or epitopes of human CD9 as the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, comprising: a heavy chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO:3; and a light chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; or a human CD9 binding fragment thereof. 98 WO 2009/023955 PCT/CA2008/001452 Claim 55. A monoclonal antibody that specifically binds the same epitope or epitopes of human CD9 as the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, comprising: a heavy chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and a light chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and variable domain framework regions from the heavy and light chains of a human antibody or human antibody consensus framework; or a human CD9 binding fragment thereof. Claim 56. A monoclonal antibody that specifically binds human CD9, wherein said monoclonal antibody comprises a heavy chain variable region amino acid sequence of SEQ ID NO:7; and a light chain variable region amino acid sequence selected of SEQ ID NO:8; or a human CD9 binding fragment thereof. Claim 57. A humanized antibody that specifically binds the same epitope or epitopes of human CD9 as the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, comprising: a heavy chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO:3; and a light chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; or a human CD9 binding fragment thereof. Claim 58. A humanized antibody that specifically binds the same epitope or epitopes of human CD9 as the isolated monoclonal antibody produced by the hybridoma cell line AR40A746.2.3 having IDAC Accession No. 141204-01, comprising: a heavy chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and a light chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and variable domain framework regions 99 WO 2009/023955 PCT/CA2008/001452 from the heavy and light chains of a human antibody or human antibody consensus framework; or a human CD9 binding fragment thereof. Claim 59. A humanized antibody that specifically binds human CD9, wherein said monoclonal antibody comprises a heavy chain variable region amino acid sequence of SEQ ID NO:7; and a light chain variable region amino acid sequence selected of SEQ ID NO:8; or a human CD9 binding fragment thereof. Composition Claim 60. A composition effective for treating a human pancreatic, prostate, ovarian, breast or colon tumor comprising in combination: an antibody or CDMAB of any one of claims 1,2,3,6,7,8,17,49,50,54,55, or 56; a conjugate of said antibody or an antigen binding fragment thereof with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells; and a requisite amount of a pharmacologically acceptable carrier; wherein said composition is effective for treating said human prostate, breast or pancreatic tumor. Claim 61. A composition effective for treating a human prostate, breast or pancreatic tumor comprising in combination: an antibody or CDMAB of any one of claims 1,2,3,6,7,8,17,49,50,54,55, or 56; and a requisite amount of a pharmacologically acceptable carrier; wherein said composition is effective for treating said human prostate, breast or pancreatic tumor. Claim 62. A composition effective for treating a human prostate, breast or pancreatic tumor comprising in combination: a conjugate of an antibody, antigen binding fragment, or CDMAB of any one of claims 1,2,3,6,7,8,17,49,50,54,55, or 56; with a member selected from the group consisting 100 WO 2009/023955 PCT/CA2008/001452 of cytotoxic moieties, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells; and a requisite amount of a pharmacologically acceptable carrier; wherein said composition is effective for treating said human prostate, breast or pancreatic tumor. Assay Kit Claim 63. An assay kit for detecting the presence of a human cancerous tumor, wherein said human cancerous tumor expresses at least one epitope of an antigen which specifically binds to the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01 or a CDMAB thereof, which CDMAB is characterized by an ability to competitively inhibit binding of said isolated monoclonal antibody to its target antigen, the kit comprising the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141204-01 or a CDMAB thereof, and means for detecting whether the monoclonal antibody, or a CDMAB thereof, is bound to a polypeptide whose presence, at a particular cut-off level, is diagnostic of said presence of said human cancerous tumor. 101 
 
   
 
 
 
 
 
 
 
 
